Sa-Hee Park

439 total citations
9 papers, 155 citations indexed

About

Sa-Hee Park is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Sa-Hee Park has authored 9 papers receiving a total of 155 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 8 papers in Hematology and 5 papers in Rheumatology. Recurrent topics in Sa-Hee Park's work include Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Eosinophilic Disorders and Syndromes (5 papers). Sa-Hee Park is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Eosinophilic Disorders and Syndromes (5 papers). Sa-Hee Park collaborates with scholars based in South Korea, Australia and India. Sa-Hee Park's co-authors include Dong‐Wook Kim, Soo‐Hyun Kim, Dongho Kim, Hyun‐Gyung Goh, Jeong Eon Lee, Timothy P. Hughes, Devendra Hiwase, Ilaria S. Pagani, Se‐Eun Jang and Haley Altamura and has published in prestigious journals such as Blood, Oncogene and British Journal of Clinical Pharmacology.

In The Last Decade

Sa-Hee Park

9 papers receiving 153 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sa-Hee Park South Korea	6	127	100	63	18	18	9	155
Kristina Myhr‐Eriksson Sweden	7	160 1.3×	95 0.9×	45 0.7×	47 2.6×	16 0.9×	7	180
Jeffrey Skinner United States	6	188 1.5×	162 1.6×	94 1.5×	24 1.3×	10 0.6×	16	220
Bonnie Kho China	5	111 0.9×	107 1.1×	44 0.7×	127 7.1×	13 0.7×	11	192
Micaela Bergamaschi Italy	7	79 0.6×	38 0.4×	18 0.3×	61 3.4×	5 0.3×	11	131
Ulrike Proetel Germany	3	227 1.8×	205 2.0×	139 2.2×	2 0.1×	26 1.4×	4	231
George Harmat Hungary	6	79 0.6×	267 2.7×	104 1.7×	46 2.6×	105 5.8×	8	290
Laure Morisset France	4	70 0.6×	39 0.4×	22 0.3×	42 2.3×	2 0.1×	5	119
I. Martinez‐Saguer Germany	8	130 1.0×	305 3.0×	110 1.7×	53 2.9×	102 5.7×	18	352
Henrike Feuersenger United States	10	62 0.5×	198 2.0×	72 1.1×	46 2.6×	53 2.9×	30	233
Sonja Visscher United States	5	74 0.6×	250 2.5×	100 1.6×	36 2.0×	92 5.1×	7	267

Countries citing papers authored by Sa-Hee Park

Since Specialization

Citations

This map shows the geographic impact of Sa-Hee Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sa-Hee Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sa-Hee Park more than expected).

Fields of papers citing papers by Sa-Hee Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sa-Hee Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sa-Hee Park. The network helps show where Sa-Hee Park may publish in the future.

Co-authorship network of co-authors of Sa-Hee Park

This figure shows the co-authorship network connecting the top 25 collaborators of Sa-Hee Park. A scholar is included among the top collaborators of Sa-Hee Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sa-Hee Park. Sa-Hee Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Shin, Dong‐Yeop, Sa-Hee Park, Eun‐Jung Jang, et al.. (2024). Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials. Leukemia Research. 143. 107542–107542. 1 indexed citations

Sari, Ita Novita, Yinggui Yang, Yoseph Toni Wijaya, et al.. (2020). AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth. Oncogene. 40(3). 603–617. 11 indexed citations

Shanmuganathan, Naranie, Ilaria S. Pagani, David M. Ross, et al.. (2020). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 137(9). 1196–1207. 46 indexed citations

Kim, Sung‐Hyun, Hari Menon, Saengsuree Jootar, et al.. (2012). Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial. Blood. 120(21). 695–695. 5 indexed citations

Kim, Dongho, Soo‐Hyun Kim, Soo-Young Choi, et al.. (2012). Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. International Journal of Hematology. 96(1). 47–57. 16 indexed citations

Kim, Dongwook, Yu Jin, Sa-Hee Park, et al.. (2010). Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia. British Journal of Clinical Pharmacology. 71(2). 199–206. 17 indexed citations

Goh, Hyun‐Gyung, Yoo‐Jin Kim, Dong‐Wook Kim, et al.. (2009). Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leukemia & lymphoma. 50(6). 944–951. 45 indexed citations

Kim, Dong‐Ho, Dong‐Wook Kim, Byung‐Sik Cho, et al.. (2009). Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations. Leukemia Research. 33(9). 1260–1265. 13 indexed citations

Kim, Dongho, Sa-Hee Park, Hana Kim, et al.. (2008). Pleural Effusion in Dasatinib-Treated Chronic Myeloid Leukemia Patients after Imatinib Failure. Blood. 112(11). 4270–4270. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact